GYG. Sohae Yang

G. Sohae Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


G. Sohae Yang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    FIGURE 3 from Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells

    by Diana Saleiro, Ewa M. Kosciuczuk, Mariafausta Fischietti, Ricardo E. Perez, G. Sohae Yang, Frank Eckerdt, Elspeth M. Beauchamp, Ye Hou, Qixuan Wang, Rona Singer Weinberg, et al.

    Gene-targeted inhibition of CHAF1B increases IFNα-inducible mRNA expression of ISGs in JAK2V617F-positive leukemic cells. qRT-PCR analyses of the indicated genes in control (Ctrl) siRNA or CHAF1B siRNA-transfected JAK2V617F-positive HEL (A) and SET-2 (B) cells, either left untreated or treated with IFNα for 6 hours. GAPDH mRNA expression was used for normalization. Data are expressed as fold change over control siRNA-transfected untreated cells (control) and represent means ± SEM of three independent experiments for each cell line. Statistical analyses were performed using one-way ANOVA followed by Tukey multiple comparisons test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. C, ChIP assay was performed in untreated and IFNα-treated (for 6 hours at 5,000 IU/mL) HEL cells at the ISG15 promoter and the IFIT1 promoter for CHAF1B binding using an anti-CHAF1B antibody. IgG antibody was used for each promoter region as negative control. Scatter dot plots show data as percent enrichment relative to input ± SEM for three independent experiments. Statistical analyses were performed using one-way ANOVA followed by Tukey multiple comparisons test. ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001. D, Immunoblot analysis of ULK1 expression in control siRNA (Ctrlsi) and ULK1 siRNA (ULK1si) transfected HEL cells either left untreated or treated with IFNα (for 6 hours at 5,000 IU/mL), as indicated. GAPDH levels were used as loading control. Blots are representative of three independent experiments used to perform ChIP assays shown in E. E, ChIP assay was performed in untreated (UT) and IFNα-treated control (Ctrl) siRNA- and ULK1 siRNA-transfected HEL cells at the ISG15 promoter and the IFIT1 promoter for CHAF1B binding using an anti-CHAF1B antibody. F, HEL cells were pretreated for 1 hour with either DMSO (Ctrl and IFNα groups) or SBI-0206965 (SBI; 10 μmol/L; SBI and SBI+IFNα groups) followed by 6 hours of treatment with either DMSO (Ctrl), SBI (10 μmol/L), IFNα (5,000 IU/mL) or SBI+IFNα, as indicated. ChIP assay was performed in HEL cells at the ISG15 promoter and the IFIT1 promoter for CHAF1B binding using an anti-CHAF1B antibody. E and F, IgG antibody was used for each promoter region as negative control. Scatter dot plots show data as percent enrichment relative to input ± SEM for three independent experiments. Statistical analyses were performed using two-way ANOVA followed by Tukey multiple comparisons test: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Relevant statistical differences are shown for the binding of CHAF1B to ISG15 and IFIT1 promoter regions between experimental conditions.

  • Open Access

    Figure S1 from Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells

    by Diana Saleiro, Ewa M. Kosciuczuk, Mariafausta Fischietti, Ricardo E. Perez, G. Sohae Yang, Frank Eckerdt, Elspeth M. Beauchamp, Ye Hou, Qixuan Wang, Rona Singer Weinberg, et al.

    Biological processes in which putative ULK1-protein complexes are involved in the cytosol.

  • Open Access

    FIGURE 1 from Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells

    by Diana Saleiro, Ewa M. Kosciuczuk, Mariafausta Fischietti, Ricardo E. Perez, G. Sohae Yang, Frank Eckerdt, Elspeth M. Beauchamp, Ye Hou, Qixuan Wang, Rona Singer Weinberg, et al.

    Mass spectrometry identification of cytosolic and nuclear putative binding partners of ULK1. A and B, Endogenous ULK1–protein complexes were immunoprecipitated (IP) using an anti-ULK1 antibody from cytosolic and nuclear fractions isolated from untreated (UT) or IFNα-treated [4 hours (4h)] HEL cells and analyzed by nLC/MS-MS. As negative control, IP with normal rabbit IgG was used instead of anti-ULK1 antibody and proteins bound to rabbit IgG were excluded from the analyses. A, Venn diagrams show the number of putative ULK1 binding partners identified only in untreated cells (blue), only in IFNα-treated cells (red), or both treated and untreated cells (black). CHAF1B was detected in both cell compartments by mass spectrometry. B, Venn diagram shows the overlap for the putative ULK1 binding partners identified under both untreated and IFNα-treated cells in the cytosolic and nuclear fractions. List of the putative ULK1 binding proteins found under these conditions on both cytosolic and nuclear compartments is shown. C, Gene ontology analyses of the 72 putative nuclear ULK1-interacting proteins identified under both untreated and IFNα-treated conditions are shown. Underlined and in bold are the biological events in which CHAF1B is involved.

  • Open Access

    FIGURE 3 from Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells

    by Diana Saleiro, Ewa M. Kosciuczuk, Mariafausta Fischietti, Ricardo E. Perez, G. Sohae Yang, Frank Eckerdt, Elspeth M. Beauchamp, Ye Hou, Qixuan Wang, Rona Singer Weinberg, et al.

    Gene-targeted inhibition of CHAF1B increases IFNα-inducible mRNA expression of ISGs in JAK2V617F-positive leukemic cells. qRT-PCR analyses of the indicated genes in control (Ctrl) siRNA or CHAF1B siRNA-transfected JAK2V617F-positive HEL (A) and SET-2 (B) cells, either left untreated or treated with IFNα for 6 hours. GAPDH mRNA expression was used for normalization. Data are expressed as fold change over control siRNA-transfected untreated cells (control) and represent means ± SEM of three independent experiments for each cell line. Statistical analyses were performed using one-way ANOVA followed by Tukey multiple comparisons test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. C, ChIP assay was performed in untreated and IFNα-treated (for 6 hours at 5,000 IU/mL) HEL cells at the ISG15 promoter and the IFIT1 promoter for CHAF1B binding using an anti-CHAF1B antibody. IgG antibody was used for each promoter region as negative control. Scatter dot plots show data as percent enrichment relative to input ± SEM for three independent experiments. Statistical analyses were performed using one-way ANOVA followed by Tukey multiple comparisons test. ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001. D, Immunoblot analysis of ULK1 expression in control siRNA (Ctrlsi) and ULK1 siRNA (ULK1si) transfected HEL cells either left untreated or treated with IFNα (for 6 hours at 5,000 IU/mL), as indicated. GAPDH levels were used as loading control. Blots are representative of three independent experiments used to perform ChIP assays shown in E. E, ChIP assay was performed in untreated (UT) and IFNα-treated control (Ctrl) siRNA- and ULK1 siRNA-transfected HEL cells at the ISG15 promoter and the IFIT1 promoter for CHAF1B binding using an anti-CHAF1B antibody. F, HEL cells were pretreated for 1 hour with either DMSO (Ctrl and IFNα groups) or SBI-0206965 (SBI; 10 μmol/L; SBI and SBI+IFNα groups) followed by 6 hours of treatment with either DMSO (Ctrl), SBI (10 μmol/L), IFNα (5,000 IU/mL) or SBI+IFNα, as indicated. ChIP assay was performed in HEL cells at the ISG15 promoter and the IFIT1 promoter for CHAF1B binding using an anti-CHAF1B antibody. E and F, IgG antibody was used for each promoter region as negative control. Scatter dot plots show data as percent enrichment relative to input ± SEM for three independent experiments. Statistical analyses were performed using two-way ANOVA followed by Tukey multiple comparisons test: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Relevant statistical differences are shown for the binding of CHAF1B to ISG15 and IFIT1 promoter regions between experimental conditions.

  • Open Access

    FIGURE 4 from Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells

    by Diana Saleiro, Ewa M. Kosciuczuk, Mariafausta Fischietti, Ricardo E. Perez, G. Sohae Yang, Frank Eckerdt, Elspeth M. Beauchamp, Ye Hou, Qixuan Wang, Rona Singer Weinberg, et al.

    Inhibition of CHAF1B increases IFNα-induced anticlonogenic effects in MPN. HEL cells (A) and SET-2 cells (B) were transfected with either control (Ctrl) siRNA or CHAF1B siRNA, and leukemic CFU-L colony formation was assessed in clonogenic assays in the presence or absence of IFNα, as indicated. Data are expressed as percentage of colony formation over control siRNA-transfected untreated cells (control), and the scatter dot plots represent means ± SEM of four independent experiments for each cell line. C, Clonogenic capability of primary malignant erythroid progenitors isolated from PV patients transfected with either control (Ctrl) siRNA or CHAF1B siRNA and either left untreated or treated with IFNα, as indicated. Data are expressed as percentage of colony formation over control siRNA-transfected untreated cells (control) and shown are means ± SEM of six independent experiments using cells from six different patients with PV. Percentages for the same patient are represented by the same symbol and different patients have different symbols. A–C, Statistical analyses were performed using one-way ANOVA followed by Tukey multiple comparisons test. *, P < 0.05; **, P < 0.01; ****, P < 0.0001.

  • Open Access

    Figure S1 from Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells

    by Diana Saleiro, Ewa M. Kosciuczuk, Mariafausta Fischietti, Ricardo E. Perez, G. Sohae Yang, Frank Eckerdt, Elspeth M. Beauchamp, Ye Hou, Qixuan Wang, Rona Singer Weinberg, et al.

    Biological processes in which putative ULK1-protein complexes are involved in the cytosol.

  • Open Access

    FIGURE 4 from Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells

    by Diana Saleiro, Ewa M. Kosciuczuk, Mariafausta Fischietti, Ricardo E. Perez, G. Sohae Yang, Frank Eckerdt, Elspeth M. Beauchamp, Ye Hou, Qixuan Wang, Rona Singer Weinberg, et al.

    Inhibition of CHAF1B increases IFNα-induced anticlonogenic effects in MPN. HEL cells (A) and SET-2 cells (B) were transfected with either control (Ctrl) siRNA or CHAF1B siRNA, and leukemic CFU-L colony formation was assessed in clonogenic assays in the presence or absence of IFNα, as indicated. Data are expressed as percentage of colony formation over control siRNA-transfected untreated cells (control), and the scatter dot plots represent means ± SEM of four independent experiments for each cell line. C, Clonogenic capability of primary malignant erythroid progenitors isolated from PV patients transfected with either control (Ctrl) siRNA or CHAF1B siRNA and either left untreated or treated with IFNα, as indicated. Data are expressed as percentage of colony formation over control siRNA-transfected untreated cells (control) and shown are means ± SEM of six independent experiments using cells from six different patients with PV. Percentages for the same patient are represented by the same symbol and different patients have different symbols. A–C, Statistical analyses were performed using one-way ANOVA followed by Tukey multiple comparisons test. *, P < 0.05; **, P < 0.01; ****, P < 0.0001.

  • Open Access

    FIGURE 1 from Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells

    by Diana Saleiro, Ewa M. Kosciuczuk, Mariafausta Fischietti, Ricardo E. Perez, G. Sohae Yang, Frank Eckerdt, Elspeth M. Beauchamp, Ye Hou, Qixuan Wang, Rona Singer Weinberg, et al.

    Mass spectrometry identification of cytosolic and nuclear putative binding partners of ULK1. A and B, Endogenous ULK1–protein complexes were immunoprecipitated (IP) using an anti-ULK1 antibody from cytosolic and nuclear fractions isolated from untreated (UT) or IFNα-treated [4 hours (4h)] HEL cells and analyzed by nLC/MS-MS. As negative control, IP with normal rabbit IgG was used instead of anti-ULK1 antibody and proteins bound to rabbit IgG were excluded from the analyses. A, Venn diagrams show the number of putative ULK1 binding partners identified only in untreated cells (blue), only in IFNα-treated cells (red), or both treated and untreated cells (black). CHAF1B was detected in both cell compartments by mass spectrometry. B, Venn diagram shows the overlap for the putative ULK1 binding partners identified under both untreated and IFNα-treated cells in the cytosolic and nuclear fractions. List of the putative ULK1 binding proteins found under these conditions on both cytosolic and nuclear compartments is shown. C, Gene ontology analyses of the 72 putative nuclear ULK1-interacting proteins identified under both untreated and IFNα-treated conditions are shown. Underlined and in bold are the biological events in which CHAF1B is involved.

  • Open Access

    FIGURE 2 from Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells

    by Diana Saleiro, Ewa M. Kosciuczuk, Mariafausta Fischietti, Ricardo E. Perez, G. Sohae Yang, Frank Eckerdt, Elspeth M. Beauchamp, Ye Hou, Qixuan Wang, Rona Singer Weinberg, et al.

    CHAF1B interacts with ULK1 in the nuclear compartment of JAK2V617F-positive cells and is overexpressed in patients with MPN. A and B, Left, ULK1–protein complexes were co-IP using an anti-ULK1 antibody from cytosolic and nuclear protein fractions isolated from untreated or IFNα-treated (10 or 240 minutes) HEL (A) or SET-2 (B) cells and then resolved by SDS-PAGE. As control, cytosolic and nuclear lysates isolated from cells treated with IFNα for 240 minutes were incubated with normal rabbit IgG (RIgG) antibody. Interaction between ULK1 and CHAF1B was assessed by immunoblotting with anti-ULK1 and anti-CHAF1B antibodies. Note: ǂ, unspecific band. A and B, Right, Equal amounts of cytosolic and nuclear protein lysates isolated from untreated and IFNα-treated HEL (A) and SET-2 (B) cells used for co-IPs were resolved by SDS-PAGE, transferred to PVDF membranes and then immunoblotted with antibodies against ULK1, CHAF1B, α-tubulin (cytosolic marker), and lamin A/C (nuclear marker), as indicated. A and B, Blots are representative of three independent experiments. C, Scatter dot plot of log2CHAF1B mRNA expression in neutrophils from healthy individuals (normal, n = 11) and patients with ET (n = 47), PMF (n = 18), and PV (n = 28). Data were extracted from NCBI GEO: GSE54646 study (21) and analyzed using GraphPad Prim 8. Shown are means ± SEM. Statistical analysis was performed using one-way ANOVA followed by Dunnett multiple comparisons test to assess P values between patients with MPN and healthy individuals. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001. Scatter dot plots of log2CHAF1B mRNA expression in neutrophils from patients with ET (green triangles), PMF (purple diamonds), and PV (red squares) carrying wild-type (WT) or mutant (MUT) JAK2 (D), CALR (E), and TET2 (F) genes (JAK2 WT: ET n = 20, PMF n = 10, PV n = 5; JAK2 MUT: ET n = 26, PMF n = 8, PV n = 23; CALR WT: ET n = 27, PMF n = 11, PV n = 26; CALR MUT: ET n = 15, PMF n = 5, PV n = 1; TET2 WT: ET n = 45, PMF n = 17, PV n = 24; TET2 MUT: ET n = 2, PMF n = 1, PV n = 4). Data were extracted from NCBI GEO: GSE54646 study (21) and analyzed using GraphPad Prim 8. Patients for which no information was available for the mutational status for the JAK2, CALR, or TET2 genes were excluded from the analysis. Shown are means ± SEM. Statistical analyses were performed using two-sample two-tailed t test: *, P < 0.05.

  • Open Access

    Data from Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells

    by Diana Saleiro, Ewa M. Kosciuczuk, Mariafausta Fischietti, Ricardo E. Perez, G. Sohae Yang, Frank Eckerdt, Elspeth M. Beauchamp, Ye Hou, Qixuan Wang, Rona Singer Weinberg, et al.

    Interferons (IFNs) are cytokines with potent antineoplastic and antiviral properties. IFNα has significant clinical activity in the treatment of myeloproliferative neoplasms (MPN), but the precise mechanisms by which it acts are not well understood. Here, we demonstrate that chromatin assembly factor 1 subunit B (CHAF1B), an Unc-51-like kinase 1 (ULK1)-interactive protein in the nuclear compartment of malignant cells, is overexpressed in patients with MPN. Remarkably, targeted silencing of CHAF1B enhances transcription of IFNα-stimulated genes and promotes IFNα-dependent antineoplastic responses in primary MPN progenitor cells. Taken together, our findings indicate that CHAF1B is a promising newly identified therapeutic target in MPN and that CHAF1B inhibition in combination with IFNα therapy might offer a novel strategy for treating patients with MPN.Significance:Our findings raise the potential for clinical development of drugs targeting CHAF1B to enhance IFN antitumor responses in the treatment of patients with MPN and should have important clinical translational implications for the treatment of MPN and possibly in other malignancies.